Abatacept decreases disease activity in a absence of CD4+ T cells in a collagen-induced arthritis model

Abatacept decreases disease activity in a absence of CD4+ T cells in a collagen-induced arthritis model

Bibliographic Details
Main Authors:	Jansen, Diahann TSL, el Bannoudi, Hanane, Arens, Ramon, Habets, Kim LL, Hameetman, Marjolijn, Huizinga, Tom WJ, Stoop, Jeroen N., Toes, René EM
Format:	Online
Language:	English
Published:	BioMed Central 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545927/

Similar Items

Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis
by: Stoop, Jeroen N., et al.
Published: (2014)

Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile
by: van der Velden, Daniël, et al.
Published: (2016)

Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis
by: Habets, Kim L.L., et al.
Published: (2015)

Abatacept in the treatment of rheumatoid arthritis
by: Vital, Edward M, et al.
Published: (2006)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
by: Schiff, Michael
Published: (2013)

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
by: van der Helm-van Mil, Annette HM, et al.
Published: (2005)

Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium
by: Suurmond, Jolien, et al.
Published: (2011)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
by: Genovese, M C, et al.
Published: (2011)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
by: Schiff, Michael, et al.
Published: (2011)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
by: Kuemmerle-Deschner, Jasmin B, et al.
Published: (2008)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
by: Katargina, LA, et al.
Published: (2011)

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
by: Moretti, D, et al.
Published: (2013)

Abatacept in psoriatic arthritis: Case report and short review
by: Ursini, Francesco, et al.
Published: (2013)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
by: Lutt, Joseph R
Published: (2009)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
by: Truchetet, Marie-Elise, et al.
Published: (2016)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
by: Peterfy, Charles, et al.
Published: (2016)

SNP algorithms for prediction of efficacy and adverse events of abatacept (ABT)
by: Middleton, James E, et al.
Published: (2012)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
by: Malaviya, Anshuman P, et al.
Published: (2012)

Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
by: Mathieu, Sylvain, et al.
Published: (2013)

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
by: Rakieh, Chadi, et al.
Published: (2014)

Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis
by: Agnes Szentpetery, et al.
Published: (2017-07-01)

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
by: Lundquist, Lisa M, et al.
Published: (2012)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
by: Harigai, Masayoshi, et al.
Published: (2016)

Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling
by: Tanita, Kayo, et al.
Published: (2015)

Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis
by: Schiff, Michael, et al.
Published: (2016)

Abatacept Improves Whole-Body Insulin Sensitivity in Rheumatoid Arthritis: An Observational Study
by: Ursini, Francesco, et al.
Published: (2015)

Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
by: Ospina, Fabio E., et al.
Published: (2014)

Squamous-cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept
by: Deidda, Arianna, et al.
Published: (2014)

Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients
by: Imberti, Luisa, et al.
Published: (2015)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
by: Alten, Rieke, et al.
Published: (2016)

Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity
by: Teng, YK Onno, et al.
Published: (2012)

Reduction of Serum ADAM17 Level Accompanied with Decreased Cytokines after Abatacept Therapy in Patients with Rheumatoid Arthritis
by: Umemura, Masayu, et al.
Published: (2014)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
by: Westhovens, Rene, et al.
Published: (2015)

"Rheumatoid Arthritis": A balanced overview of current research
by: Huizinga, Thomas WJ
Published: (2001)

Genetics of rheumatoid arthritis: what have we learned?
by: Bax, Marieke, et al.
Published: (2011)

Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics
by: Steenvoorden, Marjan MC, et al.
Published: (2006)

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
by: Smolen, Josef S., et al.
Published: (2015)

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
by: Manders, Sofie HM, et al.
Published: (2015)

Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination
by: Redeker, Anke, et al.
Published: (2016)

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
by: Emery, Paul, et al.
Published: (2015)